Loading...
XASXMSB
Market cap1.81bUSD
Dec 23, Last price  
2.53AUD
1D
3.27%
1Q
138.68%
Jan 2017
78.72%
Name

Mesoblast Ltd

Chart & Performance

D1W1MN
XASX:MSB chart
P/E
—
P/S
306.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.61%
Rev. gr., 5y
-18.80%
Revenues
6m
-21.32%
502,8852,821,7581,679,317909,807890,7085,500120,921,28538,279,90228,786,00025,980,00023,748,00042,548,0002,412,00017,341,00016,722,00032,156,0007,456,00010,211,0007,501,0005,902,000
Net income
-88m
L+7.41%
-1,470,369-8,298,587-8,728,131-10,062,379-12,285,459-14,780,89590,606,590-71,145,314-61,663,000-80,958,000-119,368,000-4,127,000-76,815,000-35,290,000-89,799,000-77,940,000-98,811,000-91,347,000-81,889,000-87,956,000
CFO
-48m
L-23.41%
-604,812-3,183,863-9,102,676-6,202,589-9,237,576-9,657,662108,228,873-72,116,783-54,081,000-81,861,000-121,709,000-87,996,000-95,471,000-75,012,000-57,790,000-56,365,000-106,681,000-65,782,000-63,269,000-48,458,000
Earnings
Feb 26, 2025

Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
URL
https://www.mesoblast.com/
IPO date
Dec 16, 2004
Employees
77
Domiciled in
AU
Incorporated in
AU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
5,902
-21.32%
7,501
-26.54%
10,211
36.95%
Cost of revenue
80,413
108,029
121,539
Unusual Expense (Income)
NOPBT
(74,511)
(100,528)
(111,328)
NOPBT Margin
Operating Taxes
(191)
(212)
(239)
Tax Rate
NOPAT
(74,320)
(100,316)
(111,089)
Net income
(87,956)
7.41%
(81,889)
-10.35%
(91,347)
-7.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
65,406
88,635
209
BB yield
-66.96%
-99.75%
-0.50%
Debt
Debt current
16,488
10,012
8,203
Long-term debt
107,013
114,215
108,973
Deferred revenue
(88,242)
Other long-term liabilities
13,120
19,112
15,023
Net debt
59,527
51,550
55,384
Cash flow
Cash from operating activities
(48,458)
(63,269)
(65,782)
CAPEX
(331)
(314)
(232)
Cash from investing activities
(97)
(194)
(232)
Cash from financing activities
40,252
74,502
(9,870)
FCF
(71,667)
(96,842)
(108,914)
Balance
Cash
62,960
70,920
60,034
Long term investments
1,014
1,757
1,758
Excess cash
63,679
72,302
61,281
Stockholders' equity
480,355
501,838
497,044
Invested Capital
548,719
565,143
469,449
ROIC
ROCE
EV
Common stock shares outstanding
98,670
77,946
68,439
Price
0.99
-13.16%
1.14
86.89%
0.61
-69.19%
Market cap
97,684
9.93%
88,858
112.85%
41,748
-66.96%
EV
157,211
140,408
97,132
EBITDA
(69,845)
(96,421)
(106,948)
EV/EBITDA
Interest
20,658
19,444
16,906
Interest/NOPBT